2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

655. Multiple Myeloma: Cellular Therapies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Omics Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Infectious Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

4045 Infection after idecabtagene vicleucel for relapsed/refractory multiple myeloma: Incidence, baseline predictors, and impact on survival — a CIBMTR analysis

Jeet Patel, DO, Matthew P Dandan, DO2, Muhammad Kashif Amin, MD, MSc, FACP3
1 The University of Kansas Cancer Center, Kansas City, Kansas, United States, The University of Kansas Medical Center, Olathe, Kansas, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 The University of Kansas Cancer Center, Kansas City, Kansas, United States

Background: Idecabtagene vicleucel (ide-cel) is a standard B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR)-T cell therapy for relapsed/refractory multiple myeloma (RRMM). These heavily pretreated, frequently hypogammaglobulinemic patients are at substantial infection risk, yet real-world predictors of infection after commercial ide-cel have not been defined at registry scale, with prior data largely limited to single-center studies.

Objective: To characterize the incidence and predictors of clinically significant infection after ide-cel for RRMM, and its association with progression-free survival (PFS) and overall survival (OS) using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry.

Methods: In this retrospective multicenter study using the publicly available CIBMTR dataset (P-6000), we analyzed 821 patients receiving commercial ide-cel for RRMM (infused 2021–2023). The outcome was clinically significant infection (first-year reporting). Baseline comparisons used chi-square and Mann-Whitney-U tests. Pre-infusion predictors were evaluated by univariable logistic regression; variables with p<0.05 on univariable analysis were considered for multivariable modeling. ECOG was excluded due to collinearity with the frailty index, and marrow plasma-cell burden was excluded due to high missingness (38%). Missing covariates were handled by multiple imputation (chained equations, M=25, Rubin’s rules), with complete-case sensitivity analysis. OS and PFS were assessed by Kaplan-Meier estimation and Cox regression; cause-specific mortality and relapse versus treatment-related mortality (TRM) were estimated by competing-risks (Aalen-Johansen) methods. Multivariable Cox models evaluated infection alongside these predictors for OS/PFS, with a landmark sensitivity analysis excluding early deaths. Cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) were treated as peri-infusion factors. Analyses used Python.

Results: Median age was 66 years (31% were ≥70); 42% were frail; median follow-up was 11.6 months. Clinically significant infection occurred in 367/821 patients (44.7%; 95% CI 41.3–48.1). On univariable analysis, infection was associated with frailty (OR 1.42), ECOG ≥2 (OR 2.89), comorbidity (OR 1.60), hemoglobin <8 g/dL (OR 1.98), platelets <50×10?/L (OR 2.14), marrow plasma cells >50% (OR 1.81), and elevated LDH (OR 1.61), but not age ≥70 (OR 1.00); peri-infusion CRS (OR 1.85) and ICANS (OR 1.70) were also associated. After multivariable adjustment and imputation, only thrombocytopenia (aOR 1.65; 95% CI 1.00–2.72; p=0.048) and elevated LDH (aOR 1.50; 95% CI 1.08–2.08; p=0.015) remained independent; frailty’s association attenuated and was no longer significant (aOR 1.21; p=0.26). Overall response rate was 73.1% and complete response rate was 25.2%. Median OS was 15.6 months, and median PFS was 8.8 months. Infection accounted for only 7.9% of deaths (vs. 75.8% due to disease progression); 12-month cumulative incidence of infection-related death was ~2.5% versus ~30% for other-cause death. Relapse, not TRM, dominated PFS events (12-month cumulative incidence 55.7% vs. 4.8%). Infection was associated with inferior OS and PFS on univariable analysis (HR 1.47 and 1.38, respectively); however, in multivariable models that included the same burden markers, this association attenuated toward the null (aHR 1.20, non-significant), while thrombocytopenia and elevated LDH independently predicted both OS and PFS in their own right (aHR 1.3–1.8, p=0.001–0.01).

Conclusion: Clinically significant infection affects nearly half of commercial ide-cel recipients but accounts for a small minority of deaths, which are chiefly driven by disease progression and relapse. Frailty was associated with infection on univariable analysis, but this effect attenuated after adjustment; thrombocytopenia and elevated LDH were the only independent predictors, and independently predicted OS/PFS as well. These routinely available pre-infusion markers can flag high-risk patients for intensified monitoring and prophylaxis. Infection's own association with survival was largely explained by this shared burden rather than reflecting an independent effect. Findings support burden-based, risk-adapted infection prevention after ide-cel; validation incorporating infection timing and pathogen-level detail is warranted.

Jeet Patel, DO: No relevant conflicts of interest to declare.